Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
- Trial name
- ANCHOR 112 (NCT00090324)
- Testing
- quetiapine fumarate tablets
- Where
- 42 sites in United States, Germany and 8 more
- Volunteers
- 249 people
- Sponsor
- AstraZeneca
Schizophrenia
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths…
- Trial name
- QUARTZ (NCT06276361)
- Testing
- Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
- Where
- Jordan
- Volunteers
- 58 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Quality of Life in Schizophrenia
Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia
Since subjective well-being and quality of life (QoL) are increasingly being recognized as important treatment outcomes in patients with schizophrenia (Hofer et al., 2004; Becker et al., 2005), the aim of this study is to…
- Trial name
- PASQAL (NCT00934726)
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Schizophrenia, Obesity
Lifestyle Intervention for Weight Gain Management for Patients With Schizophrenia
The aims of this study were to evaluate the efficacy of an intervention for weight gain management for patients from schizophrenia spectrum compared to treatment as usual (TAU), and to evaluate the effects of this program on…
- Trial name
- NCT01368406
- Testing
- wellness program
- Where
- 4 sites in Brazil
- Volunteers
- 160 people
- Sponsor
- Federal University of São Paulo
Genotype, Allelic Frequencies of Genetic Markers
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers.
- Conditions
- Genotype, Allelic Frequencies of Genetic Markers, Brain Mapping, Brain Disease
- Trial name
- NCT00001284
- Where
- United States
- Volunteers
- 2,802 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
This study will assess whether olanzapine and/or risperidone affect the way the human body uses sugar in the blood.
- Trial name
- NCT00190749
- Testing
- olanzapine, risperidone
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
SCHIZOPHRENIA 1 (Disorder)
ACT-Based Psychoeducation for Caregivers of Patients With Schizophrenia
This randomized controlled trial aims to examine the effects of an Acceptance and Commitment Therapy (ACT)-based psychoeducation program on expressed emotion, perceived family burden, and psychological flexibility among…
- Trial name
- NCT07656558
- Testing
- Acceptance and Commitment Therapy (ACT)-Based Psychoeducation Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
- Trial name
- NCT02282761
- Testing
- ITI-007
- Where
- 11 sites in United States
- Volunteers
- 450 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Psychotic Disorders
Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
This study intends to compare novel antipsychotics ziprasidone and olanzapine, to confirm the findings of an open study -where stable patients receiving olanzapine switched to ziprasidone- which showed maintenance of clinical…
- Trial name
- NCT00145444
- Testing
- olanzapine, ziprasidone
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Inherited Metabolic Disorder of Nervous System, Schizophrenia
Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.
Screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.
- Trial name
- PsyNIT (NCT05206292)
- Testing
- Sulfitest
- Where
- France
- Volunteers
- 82 people
- Sponsor
- University Hospital, Grenoble
Schizophrenia, Bipolar Disorder
Dental Status of Patients With Severe Mental Illness
The investigators aim to assess the dental status of psychiatric patients suffering from severe mental illness (schizophrenia, bipolar disorder, ptsd, resistant depression).
- Conditions
- Schizophrenia, Bipolar Disorder, PTSD, Depression
- Trial name
- SMI-DENTAL (NCT01315509)
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Hadassah Medical Organization
Schizophrenic Psychoses, Schizophrenia
Implementation of a Tool for Reduction of Cardiovascular Risk in Patients with Severe Mental Disorders ( HEALTHYHEART )
Observational study of the implementation of a Norwegian adaptation of a tool for monitoring, detection and intervention of cardiovascular risk factors in severe mental disorders.
- Conditions
- Schizophrenic Psychoses, Schizophrenia, Severe Mental Disorder
- Trial name
- HEALTHYHEART (NCT06807242)
- Where
- Norway
- Volunteers
- 270 people
- Sponsor
- Oslo University Hospital
Schizophrenia
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
- Trial name
- NCT00711269
- Testing
- SM-13496 (lurasidone HCl), Risperidone
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 460 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia
Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy
This is an observational, retrospective, non-interventional study that will include schizophrenic patients who were initiated with aripiprazole once-monthly as per normal clinical practice at least 6 months before the data…
- Trial name
- DOMINO (NCT03005769)
- Where
- 20 sites in Italy
- Volunteers
- 262 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Schizophrenia
Weight Gain Management in Patients With Schizophrenia
Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory…
- Trial name
- NCT00486005
- Testing
- Olanzapine Hydrochloride, Nizatidine
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Eli Lilly and Company
Paranoid Schizophrenia, Schizophrenia and Related Disorders
Face Your Fears: Cognitive Behavioural Virtual Reality Therapy for "Paranoia".
The study is a randomised, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment.
- Conditions
- Paranoid Schizophrenia, Schizophrenia and Related Disorders, Schizophrenia Prodromal, Schizotypal Disorder
- Trial name
- FYF (NCT04902066)
- Testing
- Cognitive Behavioural Virtual Reality Therapy., Traditional Cognitive Behavioural Therapy
- Where
- Denmark
- Volunteers
- 259 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia
A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric…
- Trial name
- NCT01606254
- Testing
- Paliperidone palmitate
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Janssen Pharmaceutical K.K.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.